EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-25446
Recombinant Monoclonal Antibody
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence, Western Blot
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit IgG Clone # HL2541
Format
Azide and BSA Free
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Synthtic peptide of human EGFR
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free
Immunocytochemistry/Immunofluorescence: EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free [NBP3-25446] -
Immunocytochemistry/Immunofluorescence: EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free [NBP3-25446] - EGFR VIII antibody [HL2541] detects EGFR VIII protein by immunofluorescent analysis. Sample: Mock and transfected 293T cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: EGFR VIII stained by EGFR VIII antibody [HL2541] (NBP3-25446) diluted at 1:500. Blue: Fluoroshield with DAPI .Western Blot: EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free [NBP3-25446] -
Western Blot: EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free [NBP3-25446] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 7.5% SDS-PAGE, and the membrane was blotted with EGFR VIII antibody [HL2541] (NBP3-25446) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.Applications for EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free
Application
Recommended Usage
Western Blot
1:500-1:3000
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Format
Azide and BSA Free
Preservative
No Preservative
Concentration
Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: EGFR
In addition to its role in normal development, EGFR mutations or overexpression is observed in many tumors, including breast cancer, non-small cell lung carcinoma (NSCLC), colon cancer, and more (3-6). Small molecule tyrosine kinase inhibitors (TKIs), like gefitinib, erlotinib, and afatinib, have shown great efficacy in treating patients with EGFR activating mutations, especially for NSCLC (4-6). However, most patients eventually develop acquired resistance to TKIs and thus combination and alternative therapies are in development (4-6). A third-generation TKI, osimertinib, is approved for NSCLC patients with resistance to first-line EGFR TKI treatment (6). Additionally, combination therapies of EGFR TKIs with monoclonal antibody immunotherapies, like anti-PD-L1, are being further investigated in clinical trials (6).
References
1. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019; 139:395-411. https://doi.org/10.1016/j.phrs.2018.11.014
2. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018; 12(1):3-20. https://doi.org/10.1002/1878-0261.12155
3. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018
4. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018; 17(1):53. https://doi.org/10.1186/s12943-018-0793-1
5. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020; 61:167-179. https://doi.org/10.1016/j.semcancer.2019.09.015
6. Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018; 17(1):38. https://doi.org/10.1186/s12943-018-0777-1
Long Name
Epidermal Growth Factor Receptor
Alternate Names
EGF R, ErbB, ErbB1, HER-1
Gene Symbol
EGFR
Additional EGFR Products
Product Documents for EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free
Product Specific Notices for EGFR Antibody (HL2541) - EGFRvIII, Mutant - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...